Skip to content

Quadro-Iliac Plane Block for Pain Control After Posterior Spinal Instrumentation Surgery

The Efficacy of Quadro-Iliac Plane Block for Postoperative Analgesia in Patients Undergoing Posterior Spinal Instrumentation Surgery: A Randomized Prospective Controlled Trial

Status
Not yet recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07711522
Enrollment
60
Registered
2026-07-17
Start date
2026-08-01
Completion date
2027-07-01
Last updated
2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posterior Spinal Instrumentation Patients

Keywords

Posterior spinal instrumentation, Postoperative analgesia, quadro-iliac plane block

Brief summary

Posterior spinal instrumentation can cause significant postoperative pain due to extensive muscle dissection, manipulation of bone tissue, and implant placement. Providing optimal analgesia in the postoperative period is important for patients' functional recovery and early mobilization. Inadequate control of postoperative pain may delay recovery, increase the risk of opioid dependence, and lead to respiratory complications. Although opioid analgesics are effective in reducing pain during the postoperative period, they are associated with side effects such as nausea, vomiting, respiratory depression, and the risk of dependence. Therefore, the use of non-opioid analgesic approaches is important for patient safety and comfort. For these reasons, regional analgesia techniques such as the modified thoracolumbar interfascial plane (TLIP) block and the erector spinae plane (ESP) block have recently become increasingly popular for postoperative pain control. The quadro-iliac plane block is a novel technique that targets the attachment area of the posterior surface of the quadratus lumborum muscle on the inner surface of the iliac crest. In this block, the spread of local anesthetic along the fascial planes surrounding the quadratus lumborum muscle may provide an anatomical mechanism contributing to analgesia of the lumbosacral, paraspinal, lower abdominal, and gluteal regions. However, as the quadro-iliac plane block is a new technique, there are not yet sufficient studies on this topic in the literature. The primary objective of our study is to evaluate the effect of ultrasound-guided quadro-iliac plane block (QIPB) on postoperative opioid consumption after posterior spinal instrumentation. The secondary objectives are to compare opioid-related side effects, such as nausea, vomiting, and respiratory depression, as well as postoperative NRS (Numeric Rating Scale) pain scores between the groups.

Interventions

All patients will have an IV PCA with fentanyl.The PCA settings will consist of a 10-µg fentanyl bolus dose with a 10-minute lockout interval.

DRUGMeperidine

If the patient's NRS is 4 or more even though 1 gr IV paracetamol and IV PCA, meperidine 0.5 mg/kg w'll be administered as rescue analgesic

An order for intravenous paracetamol 1 g every 8 hours will be placed for all patients.

Sponsors

Istanbul Medipol University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Posterior spinal instrumentation patients -

Exclusion criteria

Contraindications for regional analgesia, allergies for local anesthetics \-

Design outcomes

Primary

MeasureTime frameDescription
The effect of ultrasound-guided quadro-iliac plane block (QIPB) on postoperative opioid consumption fPostoperative 24 hoursThe primary objective of this study is to evaluate the effect of ultrasound-guided quadro-iliac plane block (QIPB) on postoperative opioid consumption following posterior spinal instrumentation surgery.

Secondary

MeasureTime frame
NRS of patientsPostoperative 24 hours
Opioid related adverse effectsPostoperative 24 hours

Countries

Turkey (Türkiye)

Contacts

CONTACTFatma P Ucar
fpinarucar@gmail.com+90 537 769 72 81

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 18, 2026